Microbio marks World Aspergillosis Day by announcing the expansion of its InfectID™-BSI qPCR test to include Aspergillus species. This significant advancement will further enhance the test’s ability to rapidly identify and differentiate the causative agents of sepsis, a life-threatening condition affecting millions worldwide. Patient trials commence this month following the successful research and development of the Aspergillus pathogen test in Microbio’s laboratories based at the Translational Research Institute.
Currently capable of identifying 20 bacterial pathogens and 6 Candida species, InfectID™-BSI is already commercially available in the UK, Europe, and India, with regulatory pathways progressing in the United States (FDA) and Australia (TGA). The addition of Aspergillus – a leading cause of invasive aspergillosis – significantly broadens the test’s scope and clinical utility. This expansion is particularly relevant given the challenges in rapid diagnosis and treatment of invasive Aspergillosis.
“Early and accurate identification of Aspergillus is essential for improving patient outcomes,” said Dr. Jan Gorm Lisby, Medical Advisor at Microbio. “The addition of Aspergillus to Microbio’s comprehensive panel strengthens their commitment to providing clinicians with the tools they need to combat sepsis effectively and save lives. Aspergillus can take several weeks to be identified by traditional blood and sputum samples, significantly delaying diagnosis and treatment. Microbio’s test can be used on both blood and sputum samples providing results in three hours, enabling clinicians to rapidly initiate appropriate therapy.”
Microbio’s proprietary rapid qPCR technology offers a crucial advantage over traditional methods, which can take days or even weeks for fungal detection. This speed is critical in sepsis management, where timely diagnosis and targeted antibiotic therapy are crucial for patient survival. By expanding InfectID™-BSI to include Aspergillus, Microbio reinforces its commitment to advancing sepsis diagnostics and saving lives.
Microbio continues to lead a paradigm shift in sepsis detection, ensuring that clinicians have the tools needed to make rapid, evidence-based treatment decisions. The expanded InfectID™-BSI panel represents another step toward reducing the global burden of sepsis.
